文献速递免疫规划卫生政策与健康促进

疫苗程序变更后18月龄大规模局部反应增加调查

Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age.
PubMed 文献 · Vaccine · 2018-09-27

加拿大魁北克省被动疫苗不良事件报告系统在2015年发现,18月龄推荐疫苗调整至包含DTaP-HB-IPV-Hib(Infanrix-hexa®)和MMRV(ProQuad®)后,大规模局部反应报告增加。一项病例对照研究纳入96例病例和494名对照,分析显示大多数大规模局部反应与Infanrix-hexa®疫苗存在因果关联,但ProQuad®与Infanrix-hexa®同肢接种未增加风险。

要点

  • 大规模局部反应更常见于Infanrix-hexa®而非DTaP-IPV-Hib疫苗(OR 5.9,95%CI 1.4-25.7)。
  • ProQuad®与Infanrix-hexa®同肢接种未增加大规模局部反应风险。
  • 多数大规模局部反应与Infanrix-hexa®疫苗存在因果关联。

核心结论

  • 本次调查提示大多数大规模局部反应与Infanrix-hexa®疫苗存在因果关联,且ProQuad®与Infanrix-hexa®同肢接种时风险未增加。
  • 鉴于乙肝疫苗覆盖率改善,获益-风险分析可能仍支持在知情家长同意下继续使用Infanrix-hexa®。

研究设计与样本

  • 病例对照研究,病例为2012年1月至2015年4月出生、在16至23月龄接种MMR±V或DTaP-IPV-Hib±HB疫苗后发生大规模局部反应的儿童,对照从省级医保数据库中同期出生儿童随机选取。
  • 分析纳入96例病例和494名对照。

主要发现

  • 96例病例中,46%为蜂窝织炎,54%为注射部位反应超出最近关节和/或持续≥4天。
  • 在不同肢体接种的39例病例中,77%的大规模局部反应位于Infanrix-hexa®接种部位,5%位于DTaP-IPV-Hib接种部位,18%位于ProQuad®接种部位。
  • Infanrix-hexa®相比DTaP-IPV-Hib疫苗的大规模局部反应频率显著更高(OR 5.9,95%CI 1.4-25.7)。
  • ProQuad®与Infanrix-hexa®同肢接种未增加大规模局部反应风险。

临床怎么用

  • 本次调查提示大多数大规模局部反应与Infanrix-hexa®疫苗存在因果关联。
  • ProQuad®与Infanrix-hexa®同肢接种未增加大规模局部反应风险。
  • 获益-风险分析可能仍支持在知情家长同意下继续使用Infanrix-hexa®。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In 2015 in Quebec, Canada, the passive vaccine adverse event reporting system detected an increase in large local reactions associated with vaccines recommended at the 18-month visit. This followed changes to the pediatric vaccine schedule to include hexavalent diphtheria-tetanus-acellular-pertusis-inactivated polio-Haemophilus influenzae type b-hepatitis B vaccine (DTaP-IPV-Hib-HB, Infanrix-hexa®, GSK) and quadrivalent measles-mumps-rubella-varicella vaccine (MMRV, ProQuad®, Merck) as 18-month booster doses. OBJECTIVES: To determine if the excess of large local reactions was caused by a specific vaccine or their co-administration in the same limb or during the same visit. METHODS: A case-control study was conducted among cases born between January 2012 and April 2015 with a large local reaction following MMR ± V or DTaP-IPV-Hib ± HB vaccines administered between 16 and 23 months of age. Controls were randomly selected from the provincial medicare database among children born during the same period. RESULTS: Our analysis included 96 cases and 494 controls vaccinated with MMRV or DTaP-IPV-Hib ± HB vaccines. Among the 96 cases, 46% had a cellulitis and 54% had an injection site reaction extending beyond the nearest joint and/or lasting ≥ 4 days. Among the 39 cases who were immunized in different limbs, 77% of the large local reactions were located at the Infanrix-hexa® site, 5% at the DTaP-IPV-Hib site and 18% at the ProQuad® site. Large local reactions were significantly more frequent with Infanrix-hexa® than with DTaP-IPV-Hib vaccine (OR 5.9 95% CI: 1.4-25.7). Administration of ProQuad® and Infanrix-hexa® in the same limb did not increase the risk of large local reactions. CONCLUSION: This investigation suggested that most large local reactions were causally associated with the Infanrix-hexa® vaccine and that the risk was not greater when ProQuad® and Infanrix-hexa® were administered in the same limb. Given the improved vaccine coverage for hepatitis B, benefit-risk analysis likely still favours ongoing use of Infanrix-hexa® with informed parental consent.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kiely M, Billard MN, Toth E, et al. Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age. Vaccine. 2018. PMID: 30269915. doi:10.1016/j.vaccine.2018.09.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。